title: see the list of  presstitutes who colluded with the clintons to defraud america and steal the election call for their arrest
text: fda to withdraw  generic adhd drugs after determining they have no therapeutic effects 
  tuesday november   by vicki batts tags fda  adhd drugs  market withdrawal naturalnews adhd medications have been subject to public scrutiny for quite some time two years ago the fda said it had discovered problems with a generic version of a popular adhd drug known as concerta the generic produced by the pharmaceutical company mallinckrodt just wasnt up to snuff and now the fda seems to finally be making moves to pull this inferior product off the shelvesgeneric drugs are approved by the fda through their abbreviated new drug application anda process in the anda process the federal agency is primarily focused on data that shows the generic drug is a bioequivalent for the reference listed drug or what many people refer to as the brand name drugthe term bioequivalent means that there is no substantial differences in bioavailability between a generic drug and the brand name product specifically it suggests that the extent and rate of absorption of two drug equivalents over the same period of time at the same dose and under the same conditions should exhibit similar results as the fda explains on their website the generic version must deliver the same amount of active ingredients into a patients bloodstream in the same amount of time as the pioneer drugunsurprisingly discrepancies in actual equivalence are often discovered after a generic has been approvedmallinckrodts concerta generic is not the only brand name knockoff under fire kremers urban pharmaceuticals a subsidiary of the lannett company also manufactures a generic form of the medication that the fdas center for drug evaluation and research cder has deemed insufficientas reported by the regulatory affairs professionals society cder tracked the issues from december  through june  ran a reanalysis of bioequivalence data and determined that the mallinckrodt product may deliver methylphenidate into the body at a slower rate than concerta during the time period of  to  hours postdosing following the cders findings mallinckrodt filed a lawsuit which was thrown out by a maryland federal judge the pharmaceutical company has since declined to voluntarily withdraw their product from the marketplace and according to the fda the drug manufacturer has yet to submit any new data or information that confirms the bioequivalence of their product to concertasimilarly the cder concluded in june of  that the data on the kremers product is insufficient to determine whether or not their generic product is therapeutically equivalent to concerta in november that year the fda announced that their product was not sufficiently equivalent to the name brandboth manufacturers may submit a request for a hearing to the fda within the next month so they can attempt to show why approval for their drugs shouldnt be withdrawnof course the fdas concerns about the apparent lack of efficacy seen in these generic drugs is rather ironic given the magnitude of other concerns surrounding these drugs in  a cbs news report revealed that  people died and  more suffered serious cardiovascular problems following the use of adhd medication in a period of just four yearsthat may not seem like a lot but is important to recall that the fda adverse event reporting system faers which is used to track such events is a voluntary system only drug manufacturers are required to report adverse events  if they know about them doctors patients and family members are under no such obligation psqh reports that drug safety experts estimate that only about  percent of all adverse events will even be reported  who is to say how many people have been harmed by adhd medications and other drugs and dont know it or havent reported itthe faers website itself states that because of its own limitations faers data cannot be used to calculate the incidence of an adverse event or medication error in the us population and yet in spite of this very statement the fda itself used this information to form a safety reportover the years several adhd medications like adderall xr have been linked to sudden death  cardiovascular problems and psychosis according to consumer reports  the longterm safety of these drugs has not been evaluated or studied sufficiently and there is evidence to suggest that the benefit of such drugs wears off after about two years many kids take adhd medication for quite a bit longer than thatin spite of all of this the fda has yet to pull these drugs from the shelves and is instead concerned with drugs that arent strong enough medications that dont work obviously dont belong in the marketplace however drugs that are killing children dont belong there either sources